SB-525334
SIGMA/S8822 - ≥98% (HPLC)
Synonym: 6-[2-tert-
CAS Number: 356559-20-1
Empirical Formula (Hill Notation): C21H21N5
Molecular Weight: 343.42
MDL Number: MFCD11045307
Linear Formula: C21H21N5
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | yellow |
| form | solid |
| InChI | 1S/C21H21N5/c1-13-6-5-7-1 |
| InChI key | DKPQHFZUICCZHF-UHFFFAOYSA |
| originator | GlaxoSmithKline |
| Quality Level | 100 ![]() |
| SMILES string | Cc1cccc(n1)-c2[nH]c(nc2-c |
| solubility | DMSO: ≥20 mg/mL |
| storage temp. | 2-8°C |
| Application: | SB-525334 was used to study TGFβ1-mediated human trophoblast differentiation.7 |
| Biochem/physiol Actions: | SB-525334 blocks the activation of Smad2/3 induced by TGFβ1 in renal proximal tubule cells.4 The sensitivity of TGFβ1 is decreased by SB-525334 that benefits the pulmonary arterial hypertension condition by reversing the pulmonary arterial pressure.5 SB-525334 is reduces the tumor incidence and size of mesenchymal tumors such as uterine leiomyoma.6 |
| Biochem/physiol Actions: | SB-525334 is a potent activin receptor-like kinase (ALK5)/ type I TGFβ-receptor kinase inhibitor with IC50 = 14.3 nM. |
| Biochem/physiol Actions: | SB-525334 is an ALK5/type I TGFβ-R kinase inhibitor. |
| Features and Benefits: | This compound was developed by GlaxoSmithKline . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Packaging: | 5, 25 mg in glass bottle |
| Hazard Codes | Xn |
| Risk Statements | 22-36/37/38 |
| Safety Statements | 26 |
| RIDADR | UN 2811 6.1 / PGIII |
| WGK Germany | WGK 3 |
| Purity | ≥98% (HPLC) |
| Storage Temp. | 2-8°C |
| UNSPSC | 12352200 |

